| Current Price | $35.07 | Mkt Cap | $1.5B |
|---|---|---|---|
| Open | $36.77 | P/E Ratio | 0.00 |
| Prev. Close | $36.80 | Div. (Yield) | $0.00 (0.0%) |
| Daily Range | $35.00 - $36.77 | Volume | 471,439 |
| 52-Wk Range | $35.00 - $63.21 | Avg. Daily Vol. | 12 |
| Current Price | $35.07 | Mkt Cap | $1.5B |
|---|---|---|---|
| Open | $36.77 | P/E Ratio | 0.00 |
| Prev. Close | $36.80 | Div. (Yield) | $0.00 (0.0%) |
| Daily Range | $35.00 - $36.77 | Volume | 471,439 |
| 52-Wk Range | $35.00 - $63.21 | Avg. Daily Vol. | 12 |
The best Bull and Bear pitches based on recency and number of recommendations.
Read the most recent pitches from players about RGNX.
Recs
meridius91
(84.92)
Submitted: 9/27/2018 12:08:01 PM :
Start Price:
$76.70
NASDAQ:RGNX Score:
-54.52
Love the optionality of partners and internal pipeline combined with a differentiated competitive advantage.
Recs
Bigsef77
(68.39)
Submitted: 9/14/2018 12:47:00 PM :
Start Price:
$77.85
NASDAQ:RGNX Score:
-59.65
Regenxbio (RGNX) has risen 121.35% YTD (year-to-date). Wall Street analysts expect it to report revenues of $194.55 million in 2018, which is a YoY (year-over-year) rise of 1,772.47%. Regenxbio expects license revenues in the second half of 2018 to be much lower than the first half of 2018 due to the non-recurring nature of those revenues.
Recs
TMFEBCapital
(89.66)
Submitted: 7/12/2018 12:41:22 PM :
Start Price:
$74.85
NASDAQ:RGNX Score:
-58.01
Big risk, big reward. Data from phase 1 trials in wet AMD and HoFH are on tap later this year. Solid balance sheet helped by $100 million payment in June from Novartis tied to NVS acquisition of AveXis, which is developing AVXS-101, an SMA gene therapy using RGNX's viral vectors.
Find the members with the highest scoring picks in RGNX.
otherAquanaut (99.76) Score: +223.23
The Score Leader is the player with the highest score across all their picks in RGNX.
|
Top Pick |
Member Name |
Member Rating |
Start Date |
Call |
Time Frame |
Start Price |
Stock Gain |
Index Gain |
Score | Commentary |
|---|---|---|---|---|---|---|---|---|---|---|
| otherAquanaut | 99.76 |
|
|
3M | $9.61 | +264.93% | +41.71% | +223.23 | 0 Comment | |
| portefeuille | 98.22 | 3/24/2016 |
|
5Y | $9.85 | +256.04% | +44.32% | +211.73 | 0 Comment | |
| portefeuille2 | 98.67 | 9/12/2016 |
|
5Y | $12.82 | +173.56% | +37.64% | +135.91 | 0 Comment | |
| clangmead | < 20 | 9/12/2016 |
|
5Y | $12.82 | +173.56% | +37.64% | +135.91 | 1 Comment | |
| efarev | 98.44 | 5/23/2017 |
|
5Y | $18.60 | +88.55% | +21.79% | +66.76 | 0 Comment | |
| Gvozden | 99.88 | 5/11/2018 |
|
1Y | $48.88 | -28.25% | +7.38% | +35.62 | 0 Comment | |
| SaintCroix | 99.06 | 1/22/2018 |
|
5Y | $27.15 | +29.17% | +3.74% | +25.43 | 0 Comment | |
| PoolSkunk | 66.54 | 3/28/2018 |
|
5Y | $29.15 | +20.31% | +12.21% | +8.09 | 0 Comment | |
| hyperionives | 82.34 | 9/26/2017 |
|
5Y | $30.65 | +14.42% | +17.24% | -2.82 | 0 Comment | |
| jeepdrew222 | 61.48 | 12/22/2017 |
|
5Y | $32.95 | +6.43% | +9.43% | -2.99 | 0 Comment |
See what the Wall Street professionals think, according to their public statements and filings.
